Radiotherapy and Oncology最新文献

{"title":"Long-Term outcomes of ablative stereotactic body radiation therapy for inoperable, non-metastatic pancreatic cancer.","authors":"Bi-Yang Cao, Le-Tian Zhang, Chen-Chen Wu, Jing Wang","doi":"10.1016/j.radonc.2025.111210","DOIUrl":"10.1016/j.radonc.2025.111210","url":null,"abstract":"<p><strong>Purpose/objective(s): </strong>To evaluate long-term outcomes and tolerability of ablative 5-fraction stereotactic body radiation therapy (SBRT) administering a biologically effective dose (BED₁₀, α/β = 10) ≥ 100 Gy in patients with inoperable, non-metastatic pancreatic cancer (PC).</p><p><strong>Materials/methods: </strong>We retrospectively reviewed a prospective registry of 88 patients with inoperable non-metastatic PC who underwent ablative 5-fraction SBRT using a CyberKnife with fiducial-based respiratory tracking between 2016 and 2020. The outcomes included overall survival (OS), progression-free survival (PFS), and treatment-related toxicity.</p><p><strong>Results: </strong>The cohort included 55 men and 33 women (median age, 65 years; range, 36-84 years). At diagnosis, 29 patients were medically inoperable, and 59 had locally advanced PC (LAPC). SBRT was administered at 50 Gy/5 fractions in 82 patients and 55 Gy/5 fractions in 6 patients. The median gross tumor volume was 33.6  cm³ (range, 3.7-167.8). With a median follow-up of 64.0 months, the median OS (mOS) was 18.1 months (95 % confidence interval [CI], 16.6-27.1) from the time at diagnosis and 15.6 months (95 % CI, 14.1-23.4) from the start of SBRT. The 1-, 2-, and 3-year OS rates were 73.9 %, 39.8 %, and 26.1 % from diagnosis, and 64.0 %, 36.0 %, and 22.1 % from SBRT, respectively. The mOS from the time at diagnosis was 18.2 months (95 % CI, 17.0-37.1) for medically inoperable patients and 17.1 months (95 % CI, 15.9-28.9) for those with LAPC, with corresponding 1-, 2-, and 3-year OS rates of 86.2 %, 41.4 %, and 31.0 % vs. 67.8 %, 39.0 %, and 23.7 %, respectively. From the start of SBRT, corresponding mOS was 16.2 months (95 % CI, 15.0-35.9) for medically inoperable patients and 14.4 months (95 % CI, 11.0-23.7) for LAPC, with 1-, 2-, and 3-year OS rates of 75.9 %, 37.9 %, and 27.6 % vs. 57.6 %, 33.9 %, and 18.6 %, respectively. Grade 3 gastrointestinal bleeding occurred in four patients (4.5 %), with no grade ≥ 4 toxicities observed.</p><p><strong>Conclusion: </strong>Ablative 5-fraction SBRT with BED₁₀ ≥ 100  Gy results in favorable survival and acceptable toxicity in inoperable, non-metastatic PC.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111210"},"PeriodicalIF":5.3,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Which ‘dose rate’ definition describes the FLASH sparing effect for scanned proton beams? A meta-analysis of skin murine data","authors":"Isabella Colizzi ,&nbsp;Per Rugaard Poulsen ,&nbsp;Brita Sørensen ,&nbsp;David Meer ,&nbsp;Antony John Lomax ,&nbsp;Serena Psoroulas","doi":"10.1016/j.radonc.2025.111206","DOIUrl":"10.1016/j.radonc.2025.111206","url":null,"abstract":"<div><div>We compiled preclinical proton PBS skin toxicity data to assess how various dose rate definitions (field, average, and dose average) explain the FLASH sparing effect. Only average dose rate (ADR), accounting for ‘effective irradiation time,’ reliably describes it. We identified high-dose and ADR regions where the effect was consistently observed.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"213 ","pages":"Article 111206"},"PeriodicalIF":5.3,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145269324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer","authors":"Neil D. Wallace ,&nbsp;Mathias Bressel ,&nbsp;Nick Hardcastle ,&nbsp;Lachlan McIntosh ,&nbsp;Nick Bucknell ,&nbsp;Tomas Kron ,&nbsp;Jason Callahan ,&nbsp;Rod Hicks ,&nbsp;David Ball ,&nbsp;Michael MacManus ,&nbsp;Nikki Plumridge ,&nbsp;Mark Shaw ,&nbsp;Daniel Steinfort ,&nbsp;Lisa Selbie ,&nbsp;Michael Hofman ,&nbsp;Shankar Siva","doi":"10.1016/j.radonc.2025.111179","DOIUrl":"10.1016/j.radonc.2025.111179","url":null,"abstract":"<div><h3>Purpose</h3><div>To utilize ⁶⁸Gallium (Ga) Ventilation-Perfusion (V/Q) 4-dimensional (4D) PET/CT to establish the impact of curative radiotherapy (RT) doses on lung ventilation and perfusion, and to evaluate associations with clinical outcomes.</div></div><div><h3>Methods and materials</h3><div>This prospective non-randomized observational clinical trial included 67 patients undergoing definitive RT +/-chemotherapy for NSCLC. Patients underwent ⁶⁸Ga 4D V/Q PET/CT at baseline, mid-treatment, and at 3- and 12-months post-treatment. Pulmonary Function Tests (PFTs) and toxicities were assessed at baseline and 3 monthly after treatment. Linear mixed models were used to assess for associations between radiotherapy dose-volume, applied to ventilated and perfused lung at 5 %, 30 % and 70 % thresholds as defined by ⁶⁸Ga 4D V/Q PET/CT, and toxicity.</div></div><div><h3>Results</h3><div>Sixty-seven patients were evaluable, of whom 44 (66 %) were male, mean age was 68, and 61 (91 %) were ECOG 0–1. Sixty-three patients completed treatment and grade ≥2 pneumonitis occurred in 20 (32 %). Lung ventilation and perfusion, and FEV1 and DLCO, fell slightly from baseline to 3-months post treatment. V54 Gy of perfused lung at the 30 % threshold was higher in those with grade ≥2 pneumonitis (median 12.9 % (IQR 8.7–14.8 %) vs 6.3 % (IQR 3.7–8.5 %), p = 0.003). No association between grade ≥2 pneumonitis and the absolute change in ventilated (p = 0.12) or perfused (p = 0.14) lung was observed.</div></div><div><h3>Conclusions</h3><div>We observed a decrease in lung ventilation and perfusion on ⁶⁸Ga 4D V/Q PET/CT from baseline to 3 months after RT. The association between the volume of well-perfused lung receiving near-therapeutic RT doses and the development of grade ≥2 pneumonitis warrants future investigation.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"213 ","pages":"Article 111179"},"PeriodicalIF":5.3,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145275798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-course radiotherapy versus long-course chemoradiotherapy in total neoadjuvant therapy of rectal cancer – A multicenter analysis of early outcomes and toxicity","authors":"Georg Wurschi ,&nbsp;Miriam Kesselmeier ,&nbsp;Melanie Schneider ,&nbsp;Jan-Niklas Becker ,&nbsp;Bernd Frerker ,&nbsp;Samuel M. Vorbach ,&nbsp;Felix Ehret ,&nbsp;Markus Diefenhardt ,&nbsp;Fabian Schunn ,&nbsp;Maria-Elena von Gruben ,&nbsp;Marcel Büttner ,&nbsp;Elgin Hoffmann ,&nbsp;Alexander Rühle ,&nbsp;Josephine Beier ,&nbsp;Simone Ferdinandus ,&nbsp;Maike Trommer ,&nbsp;Ezgi Ceren Sahin ,&nbsp;Julian Hlouschek ,&nbsp;Kynann Aninditha ,&nbsp;Daphne Schepers von Ohlen ,&nbsp;Klaus Pietschmann","doi":"10.1016/j.radonc.2025.111194","DOIUrl":"10.1016/j.radonc.2025.111194","url":null,"abstract":"<div><h3>Background and Purpose</h3><div>Total neoadjuvant therapy (TNT) improves local control and complete response (CR) rates in locally advanced rectal cancer (LARC). CR is associated with favorable local tumor control, allowing non-operative management (NOM). However, it remains unclear whether short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCRT) is preferable within TNT.</div></div><div><h3>Methods</h3><div>LARC patients undergoing TNT between 2015 and 2024 were included in this retrospective multicenter analysis (DRKS00033000). The primary endpoint was CR. Secondary endpoints comprised NOM rates, toxicity, and tumor control. Multivariable logistic regression modelling was used to assess the influence of LCRT.</div></div><div><h3>Results</h3><div>Of 295 included patients with a median age at diagnosis of 62 (Q1-Q3: 54–68) years and 210 (71.2 %) men, 172 (58.3 %) underwent LCRT. CR was achieved in 46 (37.4 %) SCRT and 96 (55.8 %) LCRT patients. Acute toxicity grade ≥ 3 occurred in 24 (20.5 %) of 117 SCRT and in 62 (36.3 %) of 171 LCRT patients. Within a median follow-up of 19.4 months (SCRT) and 19.6 months (LCRT), 23 (19.8 %) of 116 and 30 (19.4 %) of 155 patients experienced recurrence, respectively. Regression modelling revealed an increased likelihood for CR (adjusted odds ratio: 3.11; 95 % confidence interval: 1.37–7.07) and NOM (4.40; 1.46–13.21) with LCRT, whereas no significant associations of LCRT with acute toxicity (0.90; 0.40–2.02), chronic toxicity (1.16; 0.48–2.78), postoperative complications (0.89; 0.62–1.28) or recurrence (0.81; 0.31–2.16) were observed.</div></div><div><h3>Conclusion</h3><div>LCRT was associated with higher CR and NOM rates. Whether it might be preferred over SCRT for intended NOM remains a relevant question to be answered by ongoing randomized trials.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"213 ","pages":"Article 111194"},"PeriodicalIF":5.3,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145281086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term prediction of radiation-induced optic neuropathy: A mixed-effects analysis of visual field kinetics following proton therapy","authors":"Thao-Nguyen Pham ,&nbsp;Thibaud Mathis ,&nbsp;Nathan Azemar ,&nbsp;Anthony Vela ,&nbsp;Jean-Claude Quintyn ,&nbsp;Juliette Thariat","doi":"10.1016/j.radonc.2025.111205","DOIUrl":"10.1016/j.radonc.2025.111205","url":null,"abstract":"<div><h3>Introduction</h3><div>Radiation-induced optic neuropathy (RION) is a rare but serious complication of radiotherapy, leading to progressive vision loss. The temporal dynamics of RION are poorly understood, limiting effective monitoring and intervention. We developed a predictive mixed-effects model of visual field deterioration, a sensitive surrogate marker for clinically-reported RION, by integrating longitudinal clinical and dosimetric data, to anticipate long-term visual outcomes.</div></div><div><h3>Methods</h3><div>Out of a prospective database of 238 patients, 179 eyes from 105 patients treated with pencil beam scanning proton therapy were included. All selected eyes had no significant visual field deficit at baseline, defined as a mean visual sensitivity loss better than −6 dB. Baseline clinical characteristics, detailed dosimetric data, and longitudinal visual field assessments were collected. Temporal changes in mean visual sensitivity were analyzed using feature selection through random forest models and linear regression. A nonlinear mixed-effects model was then developed to predict the trajectory of visual field deterioration over time.</div></div><div><h3>Results</h3><div>Visual field deterioration progressed significantly over time, with a quadratic model best capturing the kinetics. Mean sensitivity loss accelerated with increasing age and clinical target volume. Incorporating the full dose-volume histogram, the volume of the optic chiasma received at least 40 Gy (V₄₀/chiasma), improved model performance. Simulation based on this model showed that the probability of RION increased sharply over time: 4.6 % at 2 years, and 28.3 % at 5 years.</div></div><div><h3>Conclusion</h3><div>This model confirms and expands upon prior work by showing that clinical factors can outweigh dosimetric ones in predicting RION progression. Our model was capable of predicting long-term visual outcomes even in patients with limited follow-up.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"213 ","pages":"Article 111205"},"PeriodicalIF":5.3,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145275487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to \"The role of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer at different risks of brain metastasis: A multicenter retrospective study\".","authors":"Mengjiao Guo, Dongfeng Pan","doi":"10.1016/j.radonc.2025.111203","DOIUrl":"10.1016/j.radonc.2025.111203","url":null,"abstract":"","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111203"},"PeriodicalIF":5.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultra-hypofractionated radiotherapy combined with HDR brachytherapy: An optimized treatment.","authors":"I Sidibé, M M Beaudry, D Carignan, M A Froment, W Foster, F Bachand, E Vigneault, S Magnan, S Aubin, J Morrier, E Poulin, F Lacroix, M C Lavallée, L Beaulieu, A G Martin","doi":"10.1016/j.radonc.2025.111199","DOIUrl":"https://doi.org/10.1016/j.radonc.2025.111199","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate safety and efficacy of ultra hypofractionated radiotherapy (UHF) combined with high dose rate brachytherapy boost (HDR-BB) in comparison to a moderately hypo-fractionated (MHF) regimen, in patients treated for intermediate risk prostate cancer.</p><p><strong>Materials/methods: </strong>199 patients with intermediate risk prostate cancer were recruited in the experimental UHF treatment cohort of 25 Gy in 5 fractions plus a 15 Gy HDR-BB. They were compared to two historical control groups, treated with either 36 Gy in 12 fractions (152 patients) or 37.5 Gy in 15 fractions (311 patients) with an identical HDR-BB. The study reported the biochemical cure rate (BCR) defined as PSA < 0.2 ng/ml at 4 years, as well as biochemical relapse-free survival (BRFS) and overall survival (OS). Additionally, genitourinary (GU), gastrointestinal (GI), and sexual toxicities were evaluated.</p><p><strong>Results: </strong>At the time of analysis, median follow up was respectively 36, 90 and 102 months for the UHF, 36 Gy and 37.5 Gy group. The BCR was 81.8 %, 78.4 % and 66.7 % in the UHF and both MHF groups (p = 0.11). There was no statistical difference in BRFS and OS between the three groups. There was no grade 3 toxicity in UHF group compared to 0.7 % in 36 Gy and 5.1 % in 37.5 Gy groups. No difference was found in late GU and GI toxicities between groups.</p><p><strong>Conclusion: </strong>Our study confirms UHF with HDR-BB is safe for intermediate-risk prostate cancer, reducing treatment time and patient burden. Longer follow-up is needed to confirm results.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111199"},"PeriodicalIF":5.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145259048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unilateral vs bilateral neck irradiation in lateralized oropharyngeal carcinoma: Patient selection flaws in propensity matching undermine conclusions.","authors":"Max Gau, Ali Hosni","doi":"10.1016/j.radonc.2025.111177","DOIUrl":"10.1016/j.radonc.2025.111177","url":null,"abstract":"","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111177"},"PeriodicalIF":5.3,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to commentary on \"Brachial plexopathy following stereotactic body radiation therapy in apical lung malignancies: A dosimetric pooled analysis of individual patient data\" by Sawada et al.","authors":"Hui Bai, Xiao-Feng Wang, Yi-Han Xu, Nicholas G Zaorsky, Huan-Huan Wang, Geng-Min Niu, Jia-Cheng Li, Yang Dong, Jun-Yi Li, Lu Yu, Mei-Feng Chen, Xiao-Tong Lu, Zhi-Yong Yuan, Ji-Long Yang, Mao-Bin Meng","doi":"10.1016/j.radonc.2025.111198","DOIUrl":"10.1016/j.radonc.2025.111198","url":null,"abstract":"","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111198"},"PeriodicalIF":5.3,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose ionizing radiation-induced ferroptosis leads to radiotherapy sensitization of nasopharyngeal carcinoma","authors":"Xianhuai Jin ,&nbsp;Xianlin Zeng ,&nbsp;Danwei Yang ,&nbsp;Liao Yi ,&nbsp;Weili Wu ,&nbsp;Xiaoxiao Chen ,&nbsp;Xiulin Luo ,&nbsp;Pu Xu ,&nbsp;Shuai Zhang ,&nbsp;Shichao Zhang ,&nbsp;Zuquan Hu ,&nbsp;Zhu Zeng ,&nbsp;Jinhua Long","doi":"10.1016/j.radonc.2025.111166","DOIUrl":"10.1016/j.radonc.2025.111166","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Radiotherapy (RT) is the most commonly-used treatment for nasopharyngeal carcinoma (NPC). Ferroptosis is a type of regulated cell death that is associated with cancer development. This study aims to investigate the relationship between RT and iron metabolism in NPC patients, as well as the effects of different doses of ionizing radiation (IR) on NPC cells and the role played by ferroptosis</div></div><div><h3>Methods and Materials</h3><div>A retrospective analysis was conducted on changes in iron metabolism markers—serum iron, hemoglobin, TIBC, UIBC, and transferrin saturation—before and after radiotherapy in 73 participants. CCK-8 assay was used to assess the effects of varying radiation doses on the viability of 5-8F cells, determining the radiation dose applied in this study. Real-time quantitative PCR (RT-qPCR) was performed to examine how different radiation doses affect the expression of ferroptosis-related genes (FRGs), including <em>ACSL4</em>, <em>ATP5G3</em>, <em>PTGS2</em>, and <em>IREB2</em>. Western blot analysis was employed to measure the protein expression levels of <em>GPX4</em> under varying radiation doses. The contents of lactate dehydrogenase (LDH), reactive oxygen species (ROS), malonaldehyde (MDA), [Fe2+], adenosine triphosphate (ATP), and glutathione (GSH) were assessed to evaluate the induction of ferroptosis. In addition, flow cytometry was used to analyze cell cycle distribution in NPC cells following various doses of IR. FRGs expression was assessed in NPC cell lines with varying radiosensitivity</div></div><div><h3>Results</h3><div>Compared to pre-radiotherapy levels, serum iron and transferrin saturation significantly increased after treatment, while hemoglobin and UIBC showed marked reductions. The CCK8 results indicated that after exposure to 2–18 Gy of radiation, the viability of 5-8F cells was lowest at a dose of 10 Gy. In irradiated NPC cells, mRNA expression of pro-ferroptosis factors such as <em>ACSL4</em>, <em>PTGS2</em>, and <em>IREB2</em> was generally upregulated, whereas protein levels of the anti-ferroptosis factor GPX4 were downregulated. As the IR dose increased, the contents of LDH, ROS, and MDA were upregulated, while ATP and GSH levels were downregulated. In addition, high-dose IR exposure can block NPC cells in the G₂/M phase. Moreover, we found that the expression levels of three ferroptosis driver genes were lower in radioresistant NPC cell line</div></div><div><h3>Conclusions</h3><div>High dose IR can induce ferroptosis in NPC cells, highlighting the potential for developing novel ferroptosis-based targets and overcoming radioresistance in clinical NPC treatments.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"213 ","pages":"Article 111166"},"PeriodicalIF":5.3,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}